World's first personal facemask for SARS protection

Triosyn Corp., a developer of products aimed at protecting against microbial threats, announced today that tests conducted by Health Canada’s National Microbiology Laboratory show that Triosyn T-1000™ Series Respirators protect against Severe Acute Respiratory Syndrome (SARS).

The third-party tests, which validate Triosyn’s extensive testing, demonstrate that Triosyn’s unique filtration technology eliminates SARS viral particles from the air passing through the facemask.

Health Canada, the Canadian federal bureau of health, conducted independent testing on the efficacy of Triosyn’s facemask filter to protect against SARS coronavirus, the viral agent responsible for SARS. The test involved blowing air contaminated with the SARS coronavirus through the facemask and analyzing the airstreams that passed through the facemask for the presence of viral particles. Tests were conducted at three different exposure periods: 15, 60 and 120 minutes. Health Canada’s test results show that no coronavirus particles were detected in the airstreams that passed through the Triosyn T-1000 Series Respirator during any of the three different exposure periods.

“Health Canada’s tests confirm that the T-1000 is the world’s first personal facemask that can provide protection against the potentially deadly airborne SARS virus,” said Pierre Jean Messier, Chief Executive Officer of Triosyn Corp. “Police forces in North America are currently using the T-1000 facemask and we are introducing it throughout the world.”

SARS is a potentially deadly respiratory virus, which currently has no vaccine. More than 8,400 people in 29 countries have contracted SARS and more than 900 people have died worldwide since the emergence of SARS in November 2002. The World Health Organization states that the virus can be transmitted through the air, via coughing or sneezing, on tiny droplets of bodily fluids.

The Triosyn T-1000 Respirator, a disposable personal facemask manufactured with an innovative antimicrobial technology to protect the filtration materials from microbial deterioration, is certified by the National Institute for Occupational Safety and Heath (NIOSH) as an N95 filtering facepiece respirator. It is also CE certified in Europe.

Triosyn Corp. has developed a unique antimicrobial technology for use in products designed to fight against microbial threats. In extensive third-party laboratory testing, the company’s core technology, Triosyn® resin, is proven effective against a broad spectrum of microorganisms. Triosyn® resin is versatile and equally effective in fluid, air, surface and dermatological applications.

See Triosyn Corp for more information

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Pfizer COVID-19 vaccine-associated tinnitus responds to transcranial magnetic stimulation